A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
PMV Pharmaceuticals, Inc
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Tizona Therapeutics, Inc
IDEAYA Biosciences
Eli Lilly and Company
Seagen Inc.
Sairopa B.V.
Eli Lilly and Company
Merck Sharp & Dohme LLC
Tempest Therapeutics
Merck Sharp & Dohme LLC
NuCana plc
Medicenna Therapeutics, Inc.
Carisma Therapeutics Inc
NextCure, Inc.
Pliant Therapeutics, Inc.
Corvus Pharmaceuticals, Inc.
Xencor, Inc.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Silverback Therapeutics
Incyte Corporation
Incyte Corporation
Incyte Corporation